NEULANDLABNSENeuland Laboratories Limited· PharmaceuticalsLowNeutral
Announced Fri, 4 Jul · 20:11 IST

Neuland Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 30, 2025

Board & Shareholder Meetings View source PDF

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Neuland Laboratories has issued the notice for its 41st AGM scheduled for July 30, 2025 at 10:00 AM IST, to be conducted via video conferencing. Shareholders will vote on adopting FY25 audited financial statements, declaring a final dividend of ₹12 per share (120% on face value of ₹10) for FY24-25, and ratifying the appointment of Cost Auditors (M/s. Nageswara Rao & Co.) at ₹4 lakh plus taxes. Other items include appointing M/s. P.S. Rao & Associates as Secretarial Auditors for five years (FY26-FY30) at ₹4 lakh per year, and re-appointing Dr. Christopher M. Cimarusti as a non-executive director liable to retire by rotation. The key resolution seeks shareholder approval to re-appoint Mr. Davuluri Saharsh Rao as Vice Chairman & Managing Director for another 5-year term effective June 1, 2025, with a salary range of ₹300-600 lakh per annum and a minimum guaranteed remuneration of ₹300 lakh even in years of inadequate profits.

Likely market impact

Eligible shareholders with shares held as of the record date (July 18, 2025) will receive the ₹12 final dividend, with payments starting August 11, 2025. The remote e-voting window runs from July 27-29, 2025 (cut-off date July 23, 2025), and investors should review the executive director remuneration of up to 5% of net profits, which signals a continued payout commitment from the promoter family.